Onconetix, Inc. — Form S-1/A
Filed August 31, 2026 · analyzed by the Registration Agent
S-1/A
— Neutral
significance 72/100
What the filing says
On July 28, 2026, Onconetix issued 37,812 shares of Series F Preferred Stock to Seven Knots LLC for $30,249,600 aggregate purchase price ($249,600 cash + $30,000,000 commitment fee cancellation). The Series F converts to up to 100,000,000 common shares at $0.9767/share, but current Nasdaq rules limit conversion to 789,426 shares (representing ~19.99% of pre-issuance outstanding). This S-1/A registers resale of up to 100,000,000 common shares issuable upon conversion. Company had $5.1M cash as of August 28, 2026, and substantial doubt about going concern.
Why this rating
Major financing for $3.6M market-cap company (839% of size), addresses immediate liquidity crisis; however, massive dilution and conversion restrictions, pending Realbotix merger, and going-concern doubt offset positive cash injection.
Price action (we called it neutral)
before filing · preread $0.63 ▲ 2.44% | at our read · unknown $0.61 | +10 min · unknown $0.63 ▲ 2.08% | +30 min · unknown $0.63 ▲ 2.08% | +1 hr pending | +4 hrs pending |
The stock had already moved -2.38% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from August 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.